English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
+
Pharmaceuticals
Patient Daily
| Nov 21, 2024
Las Olas Wine & Food Festival set for April; ticket sales begin Black Friday
+
Pharmaceuticals
Patient Daily
| Nov 15, 2024
Charlotte event raises $110k for lung cancer fight
+
Community
Patient Daily
| Nov 19, 2024
Babylon Dental Care Associate Dentist Absatz: ‘Older adults should follow the same dental care guidelines as anyone else’
+
Pharmaceuticals
Patient Daily
| Nov 19, 2024
Surgeon General's new report targets persistent health disparities linked to tobacco
